• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by OptimizeRx Corporation (Amendment)

    6/10/24 9:00:31 AM ET
    $OPRX
    Real Estate
    Real Estate
    Get the next $OPRX alert in real time by email
    SC 13G/A 1 oprx-sc13ga_061024.htm AMENDMENT TO FORM SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934*

    (Amendment)

     
    OptimizeRx Corporation

    (Name of Issuer)

     

    Common Stock, $0.01 par value

    (Title of Class of Securities)

     

    68401U204

    (CUSIP Number)

     

    May 31, 2024

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

      ☒ Rule 13d-1(b)
      ☐ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No . 68401U204   Page 2 of 7

     

    1

    NAME OF REPORTING PERSONS
    First Light Asset Management, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY)

    46-3521994

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING POWER

    0

     
    6

    SHARED VOTING POWER

    1,829,074

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    1,829,074

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,829,074

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.01%

     
    12

    TYPE OF REPORTING PERSON

    IA

     
             

     

     

     

     

    CUSIP No . 68401U204   Page 3 of 7  
             
    1

    NAME OF REPORTING PERSONS
    Mathew P. Arens

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY)

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United State of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING POWER

    0

     
    6

    SHARED VOTING POWER

    1,829,074

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    1,829,074

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,829,074

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.01%

     
    12

    TYPE OF REPORTING PERSON

    IN

     
                             

     

     

     

     

     

    CUSIP No. 68401U204   Page 4 of 7

     

    Item 1(a).   Name of Issuer:
        OptimizeRx Corporation
         
    Item 1(b).   Address of Issuer’s Principal Executive Offices:
        400 Water Street, Suite 200, Rochester, MI, 48307
         
    Item 2(a).   Name of Person Filing:
       

    This Schedule 13G is being jointly filed by the following:

     

    First Light Asset Management, LLC

    Mathew P. Arens (“Mr. Arens”)

       

     

    The Manager may be deemed to be the beneficial owner of the Issuer’s shares of common stock (the “Shares”). The Manager acts as an investment adviser to certain persons holding separately managed accounts with the Manager, each of whom has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, those shares. The Manager may also be deemed to be the beneficial owner of these shares because it acts as an investment adviser to certain private funds. Mr. Arens may also be deemed to be the beneficial owner of these shares because he controls the Manager in his position as managing member and majority owner of the Manager. The Manager and Mr. Arens are filing this Schedule 13G with respect to these Shares pursuant to Rule 13d-1(b) under the Act.

     

    The Manager and Mr. Arens may be deemed to be the beneficial owner of the total amount of Shares set forth across from its or his respective name in Item 4 below. The filing of this Schedule 13G shall not be construed as an admission that the reporting persons or any of their affiliates are the beneficial owner of any securities covered by this Schedule 13G for any other purposes other than Section 13(d) of the Securities Exchange Act of 1934.

         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
       

    Each of the reporting persons identified in Item 2(a) has its principal business office at:

     

    3300 Edinborough Way, Suite 201, Edina, MN 55435

         
    Item 2(c).   Citizenship:
       

    First Light Asset Management, LLC – Delaware limited liability company

    Mathew P. Arens – United States citizen

         
    Item 2(d).   Title of Class of Securities:
        Common Stock, $0.01 par value
         
    Item 2(e).   CUSIP Number:
        68401U204
         
    Item 3.

    If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

     

     

     

    CUSIP No . 68401U204   Page 5 of 7
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☒ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a) Amount beneficially owned:
       

    First Light Asset Management, LLC – 1,829,074

    Mathew P. Arens – 1,829,074

         
      (b) Percent of class:
       

    First Light Asset Management, LLC – 10.01%

    Mathew P. Arens – 10.01%

         
      (c) Number of shares as to which such person has:
         
        (i) Sole power to vote or to direct the vote
         

    First Light Asset Management, LLC – 0

    Mathew P. Arens – 0

           
        (ii) Shared power to vote or to direct the vote
         

    First Light Asset Management, LLC – 1,829,074

    Mathew P. Arens – 1,829,074

           
        (iii) Sole power to dispose or to direct the disposition of
         

    First Light Asset Management, LLC – 0

    Mathew P. Arens – 0

           
        (iv) Shared power to dispose or to direct the disposition of
         

    First Light Asset Management, LLC – 1,829,074

    Mathew P. Arens – 1,829,074

                 

     

     

     

     

     

    CUSIP No . 68401U204   Page 6 of 7

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

     

    FIRST LIGHT ASSET MANAGEMENT, LLC  

         
      Date: June 10, 2024   
       
      By: /s/ Kurt T. Peterson  
      Name: Kurt T. Peterson  
      Title: Chief Compliance Officer  
       
     

    Date:

    June 10, 2024 

     
     
      Signature: /s/ Mathew P. Arens  
      Name: Mathew P. Arens  

     

     

     

     

    CUSIP No . 68401U204 Page 7 of 7

     

    Exhibit A

    JOINT FILING AGREEMENT

     

     

    The Undersigned agree that the statement on Schedule 13G with respect to the common stock of OptimizeRx Corporation dated as of June 10, 2024, is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

     

      FIRST LIGHT ASSET MANAGEMENT, LLC
         
      By: /s/ Kurt T. Peterson
      Name: Kurt T. Peterson
      Title: Chief Compliance Officer

     

      Signature: /s/ Mathew P. Arens
      Name: Mathew P. Arens

     

     

     

     

    Get the next $OPRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPRX

    DatePrice TargetRatingAnalyst
    1/8/2025$7.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    12/20/2024$5.50Equal-Weight
    Stephens
    7/25/2024$18.50Buy
    B. Riley Securities
    4/4/2024$15.00Mkt Outperform
    JMP Securities
    1/3/2024$15.00Equal Weight
    Barclays
    2/2/2023$30.00Buy
    B. Riley Securities
    11/1/2022$19.00Buy
    Stifel
    7/15/2022$38.00Outperform
    SVB Leerink
    More analyst ratings

    $OPRX
    SEC Filings

    View All

    SEC Form DEFA14A filed by OptimizeRx Corporation

    DEFA14A - OptimizeRx Corp (0001448431) (Filer)

    6/1/26 7:30:04 AM ET
    $OPRX
    Real Estate

    SEC Form 10-Q filed by OptimizeRx Corporation

    10-Q - OptimizeRx Corp (0001448431) (Filer)

    5/13/26 4:04:37 PM ET
    $OPRX
    Real Estate

    OptimizeRx Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - OptimizeRx Corp (0001448431) (Filer)

    5/12/26 4:07:01 PM ET
    $OPRX
    Real Estate

    $OPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Greco Theresa covered exercise/tax liability with 1,793 shares, decreasing direct ownership by 2% to 71,075 units (SEC Form 4) (withholding obligation)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    5/18/26 4:44:34 PM ET
    $OPRX
    Real Estate

    Chief Executive Officer Silvestro Stephen L covered exercise/tax liability with 5,219 shares, decreasing direct ownership by 3% to 185,288 units (SEC Form 4) to satisfy withholding tax

    4 - OptimizeRx Corp (0001448431) (Issuer)

    5/18/26 4:43:36 PM ET
    $OPRX
    Real Estate

    SEC Form 3 filed by new insider Presti Mariyamma Varghese

    3 - OptimizeRx Corp (0001448431) (Issuer)

    4/22/26 10:57:29 AM ET
    $OPRX
    Real Estate

    $OPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    OptimizeRx downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded OptimizeRx from Outperform to Sector Perform and set a new price target of $6.00 from $7.00 previously

    1/8/25 8:17:01 AM ET
    $OPRX
    Real Estate

    Stephens initiated coverage on OptimizeRx with a new price target

    Stephens initiated coverage of OptimizeRx with a rating of Equal-Weight and set a new price target of $5.50

    12/20/24 7:46:38 AM ET
    $OPRX
    Real Estate

    B. Riley Securities resumed coverage on OptimizeRx with a new price target

    B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $18.50

    7/25/24 8:24:56 AM ET
    $OPRX
    Real Estate

    $OPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $OPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    OptimizeRx to Participate in Upcoming Investor Conferences

    WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: Stifel 2026 Boston Cross Sector 1x1 Conference, Boston, June 2 – 3, 202646th Annual William Blair Growth Stock Conference, Chicago, June 2 – 4, 2026 Stifel 2026 Boston Cross Sector 1x1 ConferenceDate:  Tuesday, June 2, 2026 Format: 1x1 Meetings Location: InterContinental Boston   William Blair & Company's 46th Annual Growth Stock ConferenceDate:  Wednesday, June

    6/1/26 7:30:00 AM ET
    $OPRX
    Real Estate

    DeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx's Authenticated EHR Network

    WALTHAM, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the most important decision points, today announced that DeepIntent, the leading healthcare demand-side platform (DSP), will be the first DSP to integrate OptimizeRx's proprietary electronic health record (EHR) network into its healthcare advertising platform. By combining OptimizeRx's authenticated EHR network with DeepIntent's healthcare-first DSP capabilities, this collaboration gives life sciences marketers an easier way to activate advertising within HCP wor

    5/21/26 7:30:00 AM ET
    $OPRX
    Real Estate

    OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

    – Q1 revenue totals $19.8 million– Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively– 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance unchanged at $21-$25 million– Paid off an incremental $2.7 million in principal from term loan during Q1– Completed debt refinancing, subsequent to end of Q1, with a $35 million traditional banking facility, resulting in expected $1.5 million in annual interest expense savings– Launched operating efficiency initiatives, subsequent to end of Q1, with expected annualized savings of $3 million, including $1 million in 2026 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "

    5/12/26 4:01:00 PM ET
    $OPRX
    Real Estate

    Director Lang James Paul bought $2,443,761 worth of shares (321,408 units at $7.60), increasing direct ownership by 472% to 389,452 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    3/19/25 7:40:24 PM ET
    $OPRX
    Real Estate

    CEO Febbo William J bought $100,220 worth of shares (20,000 units at $5.01), increasing direct ownership by 3% to 601,253 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    12/16/24 2:28:39 PM ET
    $OPRX
    Real Estate

    $OPRX
    Leadership Updates

    Live Leadership Updates

    View All

    OptimizeRx Releases 2026 Environmental, Social, and Governance (ESG) Report

    WALTHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2026. As a company focused on optimizing meaningful engagement opportunities at critical junctures of the healthcare journey, we remain dedicated to aligning our mission with our responsibilities as a corporate citizen. ESG Report Highlights The appointment of Mary Varghese Presti to our Board of Directors as an independent director furthers our ongoing process to refresh

    4/29/26 4:05:00 PM ET
    $OPRX
    Real Estate

    Myomo Appoints William J Febbo to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of William "Will" Febbo as a director effective April 14, 2026, to serve until the 2028 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Febbo is an accomplished executive, entrepreneur, and investor with over 30 years of experience in healthcare, financial services, and technology-driven businesses. He has successfully guided organizations through substantial growth, strategic transformations and acquisitions, and significant ca

    4/16/26 4:05:00 PM ET
    $MYO
    $OPRX
    Industrial Specialties
    Health Care
    Real Estate

    OptimizeRx Appoints Mary Varghese Presti to Board of Directors

    WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Mary Varghese Presti to its Board of Directors. The appointment of Varghese Presti as an independent director is in furtherance of the Company's ongoing process to refresh and expand its Board of Directors. Varghese Presti brings more than 25 years of experience at the intersection of healthcare, life sciences, and technology, with a track record of building and scaling platforms that translate innovation into real-world

    4/8/26 4:05:00 PM ET
    $OPRX
    Real Estate

    $OPRX
    Financials

    Live finance-specific insights

    View All

    OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

    – Q1 revenue totals $19.8 million– Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively– 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance unchanged at $21-$25 million– Paid off an incremental $2.7 million in principal from term loan during Q1– Completed debt refinancing, subsequent to end of Q1, with a $35 million traditional banking facility, resulting in expected $1.5 million in annual interest expense savings– Launched operating efficiency initiatives, subsequent to end of Q1, with expected annualized savings of $3 million, including $1 million in 2026 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "

    5/12/26 4:01:00 PM ET
    $OPRX
    Real Estate

    OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 p.m. ET

    WALTHAM, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Tuesday, May 12, 2026, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2026. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date: Tuesday, May 12, 2026 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Toll Free: 1-

    4/28/26 8:00:00 AM ET
    $OPRX
    Real Estate

    UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results

    -   Q4 revenue of $32.2 million-   Q4 gross profit increased 9% year-over-year to $24.1 million-   Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively-   Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million-   Paid off an incremental $2 million in principal from term loan during Q4-   OptimizeRx's Board authorizes a $10 million share repurchase program  WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today

    3/5/26 5:04:30 PM ET
    $OPRX
    Real Estate

    $OPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

    SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

    12/6/24 4:26:03 PM ET
    $OPRX
    Real Estate

    SEC Form SC 13G filed by OptimizeRx Corporation

    SC 13G - OptimizeRx Corp (0001448431) (Subject)

    11/14/24 3:18:35 PM ET
    $OPRX
    Real Estate

    Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

    SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

    11/14/24 11:25:34 AM ET
    $OPRX
    Real Estate